Terns Granted US Fast Track Status for NASH Candidate

Terns Pharma, a Shanghai-San Francisco biopharma, announced that TERN-101, a farnesoid X receptor (FXR) agonist, was granted Fast Track Designation by the US FDA to treat NASH. In 2018, Terns in-licensed global rights to TERN-1, together with a second NASH candidate, from Eli Lilly. Lilly Asia Ventures also invested $30 million in Tern at the same time. In preclinical testing, TERN-101 reduced liver steatosis, inflammation, ballooning and fibrosis in a NASH model. Phase I pharmacokinetics were consistent with once-daily dosing. More details.... Share this with colleagues: // //